Antineoplastic agents Langerhans cell histiocytosis Abscopal effect BRAF V600-mutation AZD9291 Adverse events Histiocytosis Cancers of the Colon Safety Molecular targeted therapies Brain Metastases Survival Colorectal carcinoma ALK rearrangement Anti-Tumor pharmacology Advanced Children Invasive cutaneous squamous cell carcinoma Prognosis Diagnosis CARMN Antibody-drug conjugate Nivolumab Polyomavirus Anti-PD1 blockade C797S Melanoma Radiotherapy BRAFV600E Targeted therapy Sonic Hedgehog Cell signalling Cemiplimab Allelic imbalance BRAF Mesenchymal stromal cells Osimertinib ACTH Chemoresistance EGFR Dabrafenib AML Ceritinib BRAFV600-mutant melanoma Cancer Biomarkers Bariatric surgery COVID-19 Merkel cell carcinoma ADN tumoral circulant Abdominal pain Biomarker ALK Systemic therapy Gastric bypass Trametinib Colorectal cancer Circulating tumor DNA Adjuvant therapy Crizotinib Plasma Biliopancreatic diversion BRAF V600E Adjuvant Adjuvant Anti-PD-1 antibody Cemiplimab Cutaneous squamous cell carcinoma Follow-up Locally advanced Metastatic Radiotherapy Surgical excision Treatment TNM classification Body mass index Circulating cell-free DNA BRAFV600E mutation Metastatic cSCC 2-chlorodeoxyadenosine Wnt Immunomodulation Radiofrequency ablation Anti-CTLA-4 Cancer Stem Cells Advanced melanoma Prognostic Cancer bronchique non à petites cellules Anti-PD1 Bone marrow niche Prevention Anti-PD-1 antibody Resistance Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Chemotherapy Immune checkpoint inhibitor Androgen insensitivity Non-small cell lung cancer Acute generalized exanthematous pustulosis Adjuvant FOLFOX Colon cancer Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Lung adenocarcinoma Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Anti-PD-1 Staging Beta-catenin Immunotherapy Immunohistochemistry